CereVasc Raises $85M to Advance Hydrocephalus Treatment

CereVasc, a medical device startup, announced the closing of an $85 million Series C funding round to develop its eShunt system for treating normal pressure hydrocephalus (NPH). The round included participation from strategic investors such as Johnson & Johnson (JNJ).

Funding Details

CereVasc raised $85 million in a Series C round led by a mix of strategic and financial investors. The full breakdown of the round structure and valuation has not been disclosed.

The Product: eShunt

The eShunt is an implantable system placed via a blood vessel to drain excess cerebrospinal fluid from the brain into the bloodstream, reducing intracranial pressure. It aims to avoid traditional open surgery that involves placing a shunt tube under the skin.

Context

Normal pressure hydrocephalus primarily affects older adults, causing gait difficulty, memory loss, and urinary incontinence. Current treatment involves surgical shunt placement, which carries a high complication rate.

What This Means for Investors

The funding round underscores growing interest in minimally invasive solutions for neurological disorders. Johnson & Johnson's (JNJ) involvement lends credibility, but commercial success hinges on clinical trial outcomes and regulatory approvals.